Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Tensor clustering with algebraic constraints gives interpretable groups of crosstalk mechanisms in breast cancer.

Seigal A, Beguerisse-Díaz M, Schoeberl B, Niepel M, Harrington HA.

J R Soc Interface. 2019 Feb 28;16(151):20180661. doi: 10.1098/rsif.2018.0661.

2.

MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.

Casaletto JB, Geddie ML, Abu-Yousif AO, Masson K, Fulgham A, Boudot A, Maiwald T, Kearns JD, Kohli N, Su S, Razlog M, Raue A, Kalra A, Håkansson M, Logan DT, Welin M, Chattopadhyay S, Harms BD, Nielsen UB, Schoeberl B, Lugovskoy AA, MacBeath G.

Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7533-7542. doi: 10.1073/pnas.1819085116. Epub 2019 Mar 21.

PMID:
30898885
3.

Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway.

Alkan O, Schoeberl B, Shah M, Koshkaryev A, Heinemann T, Drummond DC, Yaffe MB, Raue A.

Sci Signal. 2018 Jul 24;11(540). pii: eaat0229. doi: 10.1126/scisignal.aat0229.

PMID:
30042127
4.

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA.

Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16.

5.

Estimation of immune cell content in tumour tissue using single-cell RNA-seq data.

Schelker M, Feau S, Du J, Ranu N, Klipp E, MacBeath G, Schoeberl B, Raue A.

Nat Commun. 2017 Dec 11;8(1):2032. doi: 10.1038/s41467-017-02289-3.

6.

Predicting ligand-dependent tumors from multi-dimensional signaling features.

Hass H, Masson K, Wohlgemuth S, Paragas V, Allen JE, Sevecka M, Pace E, Timmer J, Stelling J, MacBeath G, Schoeberl B, Raue A.

NPJ Syst Biol Appl. 2017 Sep 20;3:27. doi: 10.1038/s41540-017-0030-3. eCollection 2017.

7.

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).

Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, Pace E, Harms B, Kim J, Kearns J, Fulgham A, Burenkova O, Grantcharova V, Yarar D, Paragas V, Fitzgerald J, Wainszelbaum M, West K, Mathews S, Nering R, Adiwijaya B, Garcia G, Kubasek B, Moyo V, Czibere A, Nielsen UB, MacBeath G.

NPJ Syst Biol Appl. 2017 Jan 5;3:16034. doi: 10.1038/npjsba.2016.34. eCollection 2017. Review.

8.

HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.

Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF.

PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr.

9.

Beyond static biomarkers--The dynamic response potential of signaling networks as an alternate biomarker?

Kim J, Schoeberl B.

Sci Signal. 2015 Dec 22;8(408):fs21. doi: 10.1126/scisignal.aad4989.

PMID:
26696629
10.

Effects of insulin-like growth factor-1 and dexamethasone on cytokine-challenged cartilage: relevance to post-traumatic osteoarthritis.

Li Y, Wang Y, Chubinskaya S, Schoeberl B, Florine E, Kopesky P, Grodzinsky AJ.

Osteoarthritis Cartilage. 2015 Feb;23(2):266-74. doi: 10.1016/j.joca.2014.11.006. Epub 2014 Nov 11.

11.

Autocrine signaling is a key regulatory element during osteoclastogenesis.

Kopesky P, Tiedemann K, Alkekhia D, Zechner C, Millard B, Schoeberl B, Komarova SV.

Biol Open. 2014 Jul 25;3(8):767-76. doi: 10.1242/bio.20148128.

12.

Deciphering the mechanism behind Fibroblast Growth Factor (FGF) induced biphasic signal-response profiles.

Kanodia J, Chai D, Vollmer J, Kim J, Raue A, Finn G, Schoeberl B.

Cell Commun Signal. 2014 May 15;12:34. doi: 10.1186/1478-811X-12-34.

13.

Analysis of growth factor signaling in genetically diverse breast cancer lines.

Niepel M, Hafner M, Pace EA, Chung M, Chai DH, Zhou L, Muhlich JL, Schoeberl B, Sorger PK.

BMC Biol. 2014 Mar 21;12:20. doi: 10.1186/1741-7007-12-20.

14.

Single timepoint models of dynamic systems.

Sachs K, Itani S, Fitzgerald J, Schoeberl B, Nolan GP, Tomlin CJ.

Interface Focus. 2013 Aug 6;3(4):20130019. doi: 10.1098/rsfs.2013.0019.

15.

MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.

Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, Razlog M, Jiao Y, Harms BD, Olivier KJ Jr, Schoeberl B, Nielsen UB, Lugovskoy AA.

Mol Cancer Ther. 2014 Feb;13(2):410-25. doi: 10.1158/1535-7163.MCT-13-0255. Epub 2013 Nov 26.

16.

Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines.

Niepel M, Hafner M, Pace EA, Chung M, Chai DH, Zhou L, Schoeberl B, Sorger PK.

Sci Signal. 2013 Sep 24;6(294):ra84. doi: 10.1126/scisignal.2004379.

17.

Rapid optimization and prototyping for therapeutic antibody-like molecules.

Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, Fitzgerald J, Nielsen U, Lugovskoy AA.

MAbs. 2013 Mar-Apr;5(2):237-54. doi: 10.4161/mabs.23363. Epub 2013 Feb 7.

18.

An expanding role for cell biologists in drug discovery and pharmacology.

Sorger PK, Schoeberl B.

Mol Biol Cell. 2012 Nov;23(21):4162-4. doi: 10.1091/mbc.E12-05-0394.

19.

Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD.

Mol Cancer Ther. 2012 Jul;11(7):1467-76. doi: 10.1158/1535-7163.MCT-11-1038. Epub 2012 May 7.

20.

Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB.

Mol Cancer Ther. 2012 Mar;11(3):582-93. doi: 10.1158/1535-7163.MCT-11-0820. Epub 2012 Jan 16.

21.

Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.

Harms BD, Kearns JD, Su SV, Kohli N, Nielsen UB, Schoeberl B.

Methods Enzymol. 2012;502:67-87. doi: 10.1016/B978-0-12-416039-2.00004-5.

PMID:
22208982
22.

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, Kung AL, Hahn WC, Drapkin R, Livingston DM, Liu JF.

Cancer Cell. 2010 Mar 16;17(3):298-310. doi: 10.1016/j.ccr.2009.12.047. Erratum in: Cancer Cell. 2010 Apr 13;17(4):412.

23.

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.

Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK.

Cancer Res. 2010 Mar 15;70(6):2485-94. doi: 10.1158/0008-5472.CAN-09-3145. Epub 2010 Mar 9.

24.

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB.

Sci Signal. 2009 Jun 30;2(77):ra31. doi: 10.1126/scisignal.2000352.

25.

Learning cyclic signaling pathway structures while minimizing data requirements.

Sachs K, Itani S, Fitzgerald J, Wille L, Schoeberl B, Dahleh MA, Nolan GP.

Pac Symp Biocomput. 2009:63-74.

26.

Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data.

Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, Lauffenburger DA, Sorger PK.

Mol Syst Biol. 2009;5:239. doi: 10.1038/msb.2008.74. Epub 2009 Jan 20.

27.

A data-driven computational model of the ErbB receptor signaling network.

Schoeberl B, Pace E, Howard S, Garantcharova V, Kudla A, Sorger PK, Nielsen UB.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:53-4.

PMID:
17946779
28.

Competing docking interactions can bring about bistability in the MAPK cascade.

Legewie S, Schoeberl B, Blüthgen N, Herzel H.

Biophys J. 2007 Oct 1;93(7):2279-88. Epub 2007 May 25.

29.

Systems biology and combination therapy in the quest for clinical efficacy.

Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK.

Nat Chem Biol. 2006 Sep;2(9):458-66.

PMID:
16921358
30.

Using computational modeling to drive the development of targeted therapeutics.

Nielsen UB, Schoeberl B.

IDrugs. 2005 Oct;8(10):822-6. Review.

PMID:
16254802
31.

Control of MAPK signalling: from complexity to what really matters.

Hornberg JJ, Binder B, Bruggeman FJ, Schoeberl B, Heinrich R, Westerhoff HV.

Oncogene. 2005 Aug 25;24(36):5533-42.

PMID:
16007170
32.

Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors.

Schoeberl B, Eichler-Jonsson C, Gilles ED, Müller G.

Nat Biotechnol. 2002 Apr;20(4):370-5.

PMID:
11923843

Supplemental Content

Loading ...
Support Center